Media

Publication: ALLOZYNE Publishes Poster Describing Impact of Novel Bispecific Th17 Inhibitor on Human Psoriatic Xenografts (June 2013)
View Poster

Press Release: ALLOZYNE Launches Next-Generation Antibody-Drug Conjugate Platform Enabled to Build Stronger and Smarter Versions of Existing Cancer Therapeutics (December 10, 2012)
View Article

Press Release: ALLOZYNE Presents Animal Data for AZ17, A Novel Bispecific Drug Candidate for Various Autoimmune Diseases, at the 42nd Annual ESDR Meeting in Venice (September 21, 2012)
View Article

Press Release: ALLOZYNE Meets with FDA for End-of-Phase 2 Meeting Regarding AZ01 for the Treatment of Relapsing-Remitting Multiple Sclerosis (March 5, 2012)
View Article

Press Release: Poniard Pharmaceuticals and ALLOZYNE Sign Definitive Merger Agreement  (June 22, 2011)
View Article

Press Release: ALLOZYNE Announces Completion of Phase IA trial by AZ01, A Long Lasting Interferon ß for Treatment of Relapsing Remitting Multiple Sclerosis  (January 10, 2011)
View Article

Press Release: ALLOZYNE Announces Positive Proof of Concept Data for AZ17, a Bispecific Th17 Antagonist for Treatment of Autoimmune Diseases (November 16, 2010)
View Article

Press Release: ALLOZYNE Solidifies Leadership Position in Site-Specific Conjugation of Protein Therapeutics Through Co-Exclusive Partnership with Sigma-Aldrich for Cycloaddition Chemistry (August 12, 2010)
View Article

Press Release: ALLOZYNE Fortifies Its Proprietary Position with a License for Click Chemistry, a Biconjugation Enabling Cycloaddition Technology from the Scripps Research Institute (July 15, 2010)
View Article

Media about ALLOZYNE